Hodgkin's disease in Turkish children: Clinical characteristics and treatment results of 210 patients


Buyukpamukcu M., Atahan L., Caglar M., Kutluk T., Akyuz C., Hazar V.

PEDIATRIC HEMATOLOGY AND ONCOLOGY, cilt.16, ss.119-129, 1999 (SCI İndekslerine Giren Dergi) identifier identifier

  • Cilt numarası: 16 Konu: 2
  • Basım Tarihi: 1999
  • Doi Numarası: 10.1080/088800199277443
  • Dergi Adı: PEDIATRIC HEMATOLOGY AND ONCOLOGY
  • Sayfa Sayıları: ss.119-129

Özet

Although Hodgkin's disease (FID) is one of the common malignancies in childhood, there is limited information from developing countries in English literature. The aim of this study is to give epidemiologic features and treatment results of 210 previously untreated children with I-ID from a developing country. Between I June 1984 and 31 December 1992, all children seen who were younger than IS years old with newly diagnosed, untreated, biopsy-proven Hodgkin's disease were included in this study. A clinical staging system was used to determine the dissemination of the disease. While patients with stage I-II disease received canape treatment protocol (three cycles COPP [cyclophosphamide, vincristine, procarbazine, prednisolone] or ABVD [doxorubicin, bleomycine, vinblastine, dacarbazine] plus low-dose involved;field radiotherapy) patients with stage III-IV disease were treated by sandwich protocol (six cycles COPP plus low-dose involved-field radiotherapy). A total of 210 patients with a median age of 8 years were eligible for this study. Mab to female ratio was 3:1 and 37 (17.6%) were less than 5 years of age. The major histologic subtype was mixed cellularity (69.6%). Overall survival rates were 91.5 and 87.7%, and event-free survival rates were 71.5 and 70.5% at 5 and 10 years, respectively. No secondary malignancy has been observed so far. The prevalance of Hodgkin's disease in young children is higher and the distribution of histologic subtypes is also different from many Western countries. Canape and sandwich treatment protocols could be used safely in clinically staged childhood HD with tolerable toxicity.